Research library

Cellcolabs cells - Clinical research overview

This library brings together peer-reviewed studies on Mesenchymal Stem Cells (MSCs) across a wide range of medical indications. Each study contributes to a deeper understanding of how MSCs support repair, regeneration, and immune balance in the body.

Cellcolabs cells

Published studies on Cellcolabs' own cells, and studies written by Cellcolabs. Filled over time as papers appear.

HLA-DR modulation and PD-1/PD-L2 checkpoint signaling identify a mechanistic potency axis for mesenchymal stromal cell immunosuppression

Mahin Nikougoftar Zarif, et al.
INTRODUCTION: Mesenchymal stromal cells exhibit potent immunomodulatory properties and are under active investigation for the treatment of immune-mediated disorders. However, their clinical translation is hindered by the lack of standardized potency assays. METHODS: Here, we established a reproducible mixed lymphocyte reaction platform by systematically optimizing peripheral blood mononuclear cell donor composition, culture conditions, and co-culture ratios to define a robust activation window.Using this optimized mixed lymphocyte reaction-based potency assay, we compared bone marrow and adipose-derived mesenchymal stromal cells across independent donor batches. RESULTS: Both sources of mesenchymal stromal cells effectively suppressed T-cell proliferation, with the adipose-derived source demonstrating greater inhibitory activity under the experimental conditions, while a conserved lower threshold of suppression was observed across both sources. Mesenchymal stromal cells reduced early (CD25+) and late (CD25+ HLA-DR+) T-cell activation, with downregulation of CD25 and HLA-DR emerging as sensitive correlates of functional potency. Notably, bone marrow-derived mesenchymal stromal cells exerted stronger suppression of late-stage HLA-DR+ activation and preferentially inhibited CD8+ T-cell expansion, demonstrating source-dependent immunomodulatory functions. Mechanistically, this suppression was associated with modulation of the PD-1 pathway, characterized by decreased soluble PD-1, increased soluble PD-L1, and induction of soluble PD-L2 by mesenchymal stromal cells. PD-L2 levels inversely correlated with T-cell proliferation in the mixed lymphocyte reaction, supporting a PD-1/PD-L2 regulatory axis linked to mesenchymal stromal cell potency. CONCLUSION: These findings support a standardized and mechanistically informed mixed lymphocyte reaction-based potency assay framework integrating functional suppression, HLA-DR modulation, and PD-1/PD-L2 pathway signaling as complementary indicators of mesenchymal stromal cell activity.

Cellcolabs R&D with Karolinska Institutet. Open access (CC BY).

Read study

An integrative interim safety overview of two open label studies with BM-MSCs

Darius Bain, et al.

Interim safety of two open-label studies (NCT06074783, NCT06087848) run by another sponsor using cells supplied by Cellcolabs. Safety only. Not indexed in PubMed.

Read study

Cell specific nutrient feeding in perfusion mode enhances hMSC growth in stirred tank bioreactor process

Johanna Pechan, et al.
Human Mesenchymal Stromal Cells (hMSCs) are a safe option for allogeneic cell therapy across various diseases, but their manufacturing process requires improvement to broaden accessibility. In this study, a state-of-the-art planar multi-vessel process was transferred to a stirred tank bioreactor using microcarriers to support the growth of adherent cells. The frequent medium exchange strategy from planar culture guided the design of the bioreactor process. However, complete medium changes in the bioreactor resulted in limited cell expansion and higher glucose consumption compared to planar culture. To enhance expansion, a 0.1 L perfusion bioreactor was tested, enabling continuous medium exchange. Three perfusion approaches were evaluated: (1) maintaining a target cell-specific glucose consumption rate, (2) varying the perfusion rate, and (3) applying a cell-specific perfusion rate. Implementing targeted glucose feeding (TAFE) reduced lactate production, while increasing perfusion rates improved cell density. The highest expansion was achieved using a cell-specific perfusion rate of 5 nL cell-1 day-1 combined with a target glucose consumption rate (qglc) of 15 pmol cell-1 day-1, resulting in a 5.4-fold higher expansion factor than daily medium changes in stirred tank bioreactors. This optimized process represents a key advancement toward producing clinically relevant quantities of hMSCs.

AdBIOPRO (KTH competence centre) with Cellcolabs co-authors.

Read study